Skip to Content

Posts tagged with "Business and Markets"

  • Business and Markets

    The Latest on China

    China’s impact on biopharma has been a perennial story in the press (and on this blog). The big picture has been the interplay between the “China as a source of cheap scientific labor” story, the “Big Western drug companies setting up divisions in China” one, and “When will China have its own research-driven dru… Read More
  • Business and Markets

    Mongersen Fails

    Readers may recall a post here last year about an odd trial of an antisense drug for Crohn’s disease. Celgene had acquired the drug (mongersen, GED-301) from Nogra Pharma of Ireland back in 2014 as a late-stage candidate, and for a while, things looked good. In fact, going back and reading the stories, you’d think that… Read More
  • Business and Markets

    Incyte and Flexus: The Grappling Continues

    A couple of years back, I wrote about a case of accused stolen pharma intellectual property that looked like it would be heading to court. And here we are in 2017, and it’s. . .heading to court. The wheels of the law have been grinding along this whole time in the matter of Incyte and… Read More
  • Business and Markets

    A Bit About Biopharma Investing

    Well, as predicted here (and many other places), Merck announced yesterday that they are indeed not going to try to seek approval for their CETP inhibitor, anacetrapib. That’s despite an ostensibly positive Phase III trial, but it apparently wasn’t positive enough to take the risk of bringing this drug before the FDA (or to the… Read More
  • Business and Markets

    Knock Six Years Off Your Timeline. Um.

    There’s only one honest answer to the question “How long does it take to develop a new drug?”, and that’s “Too @#$! long”. In the same way, the only honest answer to “What are the average chances for a drug candidate’s success?” is “Too @#$! low”. The combination of those two factors… Read More
  • Alzheimer's Disease

    Bad News – But Not the Unexpected Kind

    Yesterday was not a good day for small companies trying to get drugs to regulatory approval for tough diseases. You may well remember Axovant, a company that I’ve written about several times (most recently here). To recap, AXON was started by a fund manager, who bought a failed Alzheimer’s candidate off GSK, announced that they’d… Read More
  • Business and Markets

    It Costs More Than This

    Here’s another paper on the cost to develop a new drug, a topic about which, I’m convinced, debate will never end. This one is designed as a response to the Tufts estimates on these costs, and I’m not going to help much, because I have some things to debate about this paper myself. The authors… Read More
  • Business and Markets

    Allergan Pulls A Fast One

    Friday brought news of a drug-company maneuver that I had never heard of, and didn’t even realize was possible. First, a bit of background; the stage needs to be set properly. One of Allergan’s products is Restasis, used for dry eyes, which is an opthalmic formulation of cyclosporine. It’s a valuable part of their portfolio… Read More
  • Business and Markets

    Lilly Cuts Back, Again

    The Big Pharma story at the moment, sad to say, is that Eli Lilly is shedding a lot of employees: 3,500 or so (2000 of them in the US), about 8.5% of their global workforce. Their site in Bridgewater (NJ) is being closed, and interestingly, so is their site in Shanghai, which makes them (if… Read More
  • Biological News

    Good Craziness and Bad Craziness

    It’s fair to say that there’s a high level of excitement these days in biopharma (and the associated academic disciplines) due to the tools we have at our disposal these days. CRISPR and other gene-editing technologies, new looks at RNA, chromatin, and epigenetics, all sorts of unusual modes for altering cells and whole-animal phenotype… Read More
...234...